Asset
IBUDILAST
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02714036 | phase1_2 | completed | 2016-05-06 | 2019-12-31 | MediciNova | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) |
| NCT04429555 | phase2 | completed | 2021-01-11 | 2022-06-30 | MediciNova | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS |
| NCT04057898 | phase2_3 | active_not_recruiting | 2020-05-28 | 2027-04-01 | MediciNova | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS |
| NCT02238626 | phase2 | completed | 2014-09-01 | 2017-08-01 | MediciNova | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) |
| NCT04054206 | phase1 | completed | 2019-06-24 | 2019-07-17 | MediciNova | Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.